I was immediately intrigued by the title of the paper by Friedman and colleagues [7] . A tumult of thoughts ensued as I fought for a basis for linking organosiloxanes with the treatment of neurodegenerative disease! Needless to say, I was surprised at the authors' contention that organosiloxanes might be used therapeutically to prevent or dissolve metal-mediated deposits of brain amyloid though my surprise was tempered by knowledge of an earlier and similar suggestion by Fasman and colleagues that inorganic silicates might be used to the same end [6] . Friedman et al. have acknowledged Fasman et al. as the origin of their idea but were they mislead by the earlier publication? According to the abstract and conclusions Fasman et al. demonstrated that an aluminium-induced transition towards β-sheet conformers of Aβ 42 could be reversed to random coil soluble forms of the peptide by the addition of sodium orthosilicate (Na 4 SiO 4 ) and, crucially, that this effect was attributable to the tight binding of Al
I was immediately intrigued by the title of the paper by Friedman and colleagues [7] . A tumult of thoughts ensued as I fought for a basis for linking organosiloxanes with the treatment of neurodegenerative disease! Needless to say, I was surprised at the authors' contention that organosiloxanes might be used therapeutically to prevent or dissolve metal-mediated deposits of brain amyloid though my surprise was tempered by knowledge of an earlier and similar suggestion by Fasman and colleagues that inorganic silicates might be used to the same end [6] . Friedman [2] . My interpretation of Friedman et al., at least in its original form, is that the authors were mislead to the extent that they have looked to extend Fasman's earlier studies by appending a notional SiO 4− 4 functionality to a lipid soluble carrier to improve the accessibility of such a group to a target site in the brain. Once in situ in sufficiently high concentrations the organosilicate would titrate aluminium, and other metals, out of precipitated deposits of Aβ 42 and prevent any further metal-amyloid induced neuronal damage [9] .
Friedman et al. have shown that both aluminium and iron were able to promote the formation of β-sheet conformers of Aβ 42 and, indeed, that the addi-tion of organosiloxanes prevented and/or reversed such conformational transitions. The observation of metalinduced formation of β-sheets is not new [1, 8] but how might their prevention/reversal using organosiloxanes be explained? No evidence is offered that any of the organosiloxanes bind any metals under any set of conditions. There is no evidence in the scientific literature that any of the organosiloxanes used by Friedman et al. will bind metals and we have shown that neither dimethylsilanediol (DMSD) nor polydimethylsiloxane (PDMS) binds aluminium [5] . Perhaps a more likely explanation of the observed effects may be related to changes in the hydrophobicity of the solvent mixture upon addition of the organosiloxanes? Such differences could act so as to promote conformational changes in Aβ 42 such that metal-binding sites are either protected (thus preventing metal-induced effects) or rendered unstable/ineffective (acting so as to reverse metal-induced effects).
Even allowing for the proviso that metal-induced aggregation and precipitation of Aβ 42 has any role to play in the aetiology of Alzheimer's disease [3] I remain unconvinced that organosiloxanes would have any therapeutic value. I worry about how they could be delivered to their target sites at sufficient concentrations to have any effect and I worry about what happens to the metal once it has been purged from its amyloid sink. There is one form of silicon, the biologically available form of silicon known as silicic acid (Si(OH) 4 ), which binds aluminium, is freely permeable throughout the body and has been shown to facilitate the excretion of aluminium from the body [4] . Friedman et al. seem as yet unaware of its potential therapeutic value in neurodegenerative disease.
